OR WAIT null SECS
Partnership Designed to Expand ePRO Options Available in Clinical Research
ROCKVILLE, MD and PITTSBURGH, PA- June 22, 2005 -- InforMedix Holdings, Inc. (OTCBB: IFMX) and invivodata, inc. (www.invivodata.com), today announced a strategic partnership for the marketing, sale, distribution, and implementation support of InforMedix's Med-eMonitor(tm) System to invivodata's global base of pharmaceutical and biotech company clients. The collaboration combines a highly effective solution for managing patient drug safety and dose-response data in clinical trials, with a market leader in providing electronic Patient Reported Outcomes (ePRO) solutions to the global clinical trials market. Trial sponsors will benefit from having a choice of appropriate tools to collect critical data directly from patients.
According to the terms of the agreement, invivodata will deliver InforMedix's Med-eMonitor System as an integral part of its product line, worldwide. invivodata's current ePRO solutions include DiaryPRO(tm), a handheld electronic diary, and SitePRO(tm), a site-based data collection tool for capturing PRO data. Both of these products include access to the industry's leading patient and site management system for ePRO data, which gives researchers and sponsors visibility into study progress and improves trial efficiencies. invivodata is the undisputed leader in the appropriate use of proven methodologies and technologies to collect valid PRO data. As a result, invivodata leads the industry in the delivery of proven clinical research results and consistent business growth, as demonstrated by their recently completed 11th consecutive quarter of revenue growth.
invivodata will offer the Med-eMonitor System to its growing client base, particularly to those sponsors conducting clinical trials requiring medication adherence and patient dose-response data. A number of invivodata's clients have requested a solution that provides Med-eMonitor's range of functionality.
InforMedix will grant invivodata limited exclusive rights among eDiary providers to distribute the Med-eMonitor System in the clinical trials market. invivodata will also provide clinical trial implementation services including training, field support, and first-level help desk support to clients who use Med-eMonitor in a trial. Through cooperative development, both companies will contribute to integration efforts between InforMedix's Med-eMonitor and Med-eXpert Systems and invivodata's back end trial management system.
Dr. Bruce Kehr, CEO of InforMedix commented: "We are very excited to partner with invivodata, a leader in ePRO solutions for the global clinical trials market. invivodata's strong reputation within the pharmaceutical and biotech industries will support our efforts to expand the distribution of our proprietary solution. invivodata's capabilities as a global implementation partner for the clinical trials market allows InforMedix to focus more resources into providing products and services to the disease management and home healthcare markets."
Doug Engfer, President and CEO of invivodata stated, "The addition of the Med-eMonitor System to our product portfolio offers our clients a unique combination of ePRO capabilities with medication dispensing to enhance medication compliance, and drug safety monitoring and reporting to improve patient safety. We view this partnership as an opportunity to further expand our strength in this arena and continue our rapid revenue growth."
About InforMedix, Inc.
InforMedix has developed the Med-eMonitor System to provide real-time medical management and patient communications for clinical drug trials and disease management markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable pharmaceutical and biotechnology companies, medical researchers, and disease management programs to efficiently monitor and manage patients' medication compliance, protocol adherence, clinical response, and drug safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in clinical drug trials and disease management programs. The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 12 patents pending. InforMedix's patents have been cited as prior art by patent examiners in over 150 other issued patents.
To find out more about InforMedix, Inc., visit our website at www.informedix.com.
About invivodata, Inc.
invivodata (www.invivodata.com) combines behavioral science, information technology and clinical expertise to capture clinical trial data of the highest integrity directly from patients. invivodata's electronic patient reported outcomes (PRO) system delivers high-quality patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague self-report studies. The invivodata solution, which includes DiaryPRO(tm) for real-time PRO data collection and SitePRO(tm) for site-based PRO data collection, provides access to study data, giving researchers and sponsors visibility into study progress and improving trial efficiencies. invivodata's solution has been used in more than 100 trials involving over 35,000 patients. It has also collected nearly 50 million patient-initiated records, and is the only eDiary system that has delivered key PRO data in support of multiple FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters are in London, England; and its technology development center is in Scotts Valley, Calif., USA.